Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections

Talal Hilal, Juan C. Gea Banacloche, Jose F. Leis

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the world. Patient with CLL are at particular risk for infections due to inherent disease-related immune dysfunction in addition to the effect of certain systemic therapies on the immune system. The advent of B-cell receptor (BCR) inhibitors such as ibrutinib and idelalisib has led to a practice change that utilizes these targeted agents in the treatment of CLL, either in place of chemoimmunotherapy (CIT) or in later line settings. In this paper, we review the pathophysiology of immune dysfunction in CLL, the spectrum of immunodeficiency with the various therapeutic agents along with prevention strategies with a focus on targeted therapies.

Original languageEnglish (US)
JournalBlood Reviews
DOIs
StateAccepted/In press - Jan 1 2018

Keywords

  • Chronic lymphocytic leukemia
  • CLL
  • Ibrutinib
  • Idelalisib
  • Targeted therapy
  • Venetoclax

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections'. Together they form a unique fingerprint.

Cite this